Featured Story

  • Buzz: Shire is coming back for Baxalta with cash-plus-stock bid

    Shire is reportedly preparing a new cash-plus-stock offer for Baxalta. The report comes almost four months after a $30 billion all-stock proposal was dismissed by Baxalta, leaving Shire to ponder how to advance its ambitions to become a rare disease powerhouse.

Lilly's middling lung cancer drug wins FDA approval with a restrictive label

Eli Lilly won FDA approval for a lung cancer treatment that posted only a marginal survival benefit in late-stage clinical trials, gaining clearance to treat a small population of patients with particularly serious disease.

Allergan scoops up some CNS drugs as its $160B Pfizer merger pends

Allergan, seeking to burnish its reputation in R&D, bought into some early-stage treatments for autism and obsessive-compulsive disorder as it prepares to join forces with Pfizer in a massive merger.

Teva wagers up to $410M on Heptares' migraine program

Heptares Therapeutics, acquired by Japan's Sosei earlier this year, signed a deal with Teva Pharmaceutical to co-develop novel migraine treatments, getting in line for as much as $410 million.

Novo Nordisk taps Ablynx in a $400M deal

Novo Nordisk signed a deal with Ablynx worth up to €377 million ($400 million) to collaborate on so-called nanobodies, antibody fragments designed to split the difference between biologics and small-molecule drugs.

Aduro slips after trial patient comes down with a dangerous infection

Aduro BioTech, developing an immunotherapy combination treatment for cancer, watched its share price dip on Tuesday after quietly disclosing that a trial patient developed a serious infection tied to the company's re-engineered bacterial treatment.